نسخة كاملة جاهزة للنقل مباشرة إلى Excel، تشمل:
Medications Table: كل الأدوية 1–30 مع الأعمدة الإضافية كاملة (Renal_Adjustment, Pregnancy_Safe, Contains_Insulin, Contains_Metformin, Priority, Preferred_In, Avoid_In).
Clinical Scenarios: كل السيناريوهات 1–15 مع الفحوصات والمتابعة (Suggested_Labs, Follow_Up_Interval, Notes).
Patient Input Table: جدول جاهز لإدخال بيانات المريض.
Output Table: جدول لتوليد الروشتة + الفحوصات + التوصيات تلقائيًا.
1️⃣ Medications Table (1–30)
Drug_ID
Generic_Name
Brand_Name
Category
Subcategory
Route
Standard_Dose
Preferred_In
Avoid_In
Priority
Renal_Adjustment
Pregnancy_Safe
Contains_Insulin
Contains_Metformin
1
Metformin
Glucophage; Siofor; Cidophage; Diaformin; Metforal
Biguanide
—
Oral
500–1000 mg BID
Type 2 DM, Obese
eGFR < 30
1
Yes
Limited
No
Yes
2
Glimepiride
Amaryl; Glimadel; Glimic; Diamicron MR
Sulfonylurea
—
Oral
1–4 mg daily
Type 2 DM (non-obese)
Elderly, Hypoglycemia-prone
2
Yes
Limited
No
No
3
Gliclazide
Diamicron MR; Uni-Diamicron; Glizide
Sulfonylurea
MR
Oral
30–120 mg daily
Type 2 DM
Renal failure, Elderly
2
Yes
Limited
No
No
4
Empagliflozin
Jardiance
SGLT2
—
Oral
10–25 mg OD
Type 2 DM + CVD/CKD
eGFR < 30, Dehydration
1
Yes
No
No
No
5
Dapagliflozin
Forxiga
SGLT2
—
Oral
5–10 mg OD
Type 2 DM + HF
eGFR < 30
1
Yes
No
No
No
6
Canagliflozin
Invokana
SGLT2
—
Oral
100–300 mg OD
Type 2 DM obese
eGFR < 30
2
Yes
No
No
No
7
Sitagliptin
Januvia; Sitaphage
DPP4
—
Oral
100 mg OD
T2DM elderly/renal
Pancreatitis
1
Minimal
Limited
No
No
8
Linagliptin
Trajenta
DPP4
—
Oral
5 mg OD
CKD (no dose adjust)
Pancreatitis
1
Minimal
Limited
No
No
9
Vildagliptin
Galvus; Galvus Met
DPP4
—
Oral
50 mg BID
Type 2 DM
Hepatic impairment
2
Yes
Limited
No
No
10
Liraglutide
Victoza
GLP1
—
SC
0.6 → 1.8 mg daily
Obese T2DM, CV risk
Pregnancy
2
Yes
No
No
No
11
Semaglutide
Ozempic
GLP1
—
SC
0.25 → 1 mg weekly
Obese T2DM
Thyroid tumor history
1
Yes
No
No
No
12
Insulin Glargine
Lantus; Basaglar; Toujeo
Insulin
Long-acting
SC
10–40 units/day
Type 1, Type 2 uncontrolled
Hypoglycemia
1
Yes
No
Yes
No
13
Insulin Degludec
Tresiba
Insulin
Ultra-long
SC
Individualized
CKD, elderly
—
1
Yes
No
Yes
No
14
Insulin Detemir
Levemir
Insulin
Long-acting
SC
Individualized
Type 1, Type 2
Hypoglycemia
2
Yes
No
Yes
No
15
Insulin Aspart
Novorapid; Fiasp
Insulin
Rapid
SC
0.1–0.2 units/kg/meal
Postprandial control
Frequent hypoglycemia
1
Yes
No
Yes
No
16
Insulin Lispro
Humalog
Insulin
Rapid
SC
0.1–0.2 units/kg/meal
Flexible meals
Hypoglycemia
1
Yes
No
Yes
No
17
Insulin 70/30 mix
Mixtard 30; Humulin M3
Insulin
Premix
SC
Individualized BID
Fixed meal pattern
Variable appetite
2
Yes
No
Yes
No
18
Pioglitazone
Actos
TZD
—
Oral
15–45 mg daily
Insulin resistance + NAFLD
Heart failure, Edema
2
Yes
Limited
No
No
19
Acarbose
Glucobay
Alpha-glucosidase
—
Oral
50–100 mg TDS
Postprandial control
GI upset, IBD
3
No
Limited
No
No
20
Repaglinide
Novonorm
Meglitinide
—
Oral
0.5–2 mg premeal
Irregular meal times
Liver disease
3
Yes
Limited
No
No
21
Metformin + Sitagliptin
Janumet; Sitaphage
Combo (Biguanide+DPP4)
—
Oral
50/500 – 50/1000 mg BID
T2DM needing dual oral therapy
eGFR < 30
1
Yes
Limited
No
Yes
22
Metformin + Vildagliptin
Galvus Met
Combo (Biguanide+DPP4)
—
Oral
50/500 – 50/1000 mg BID
Type 2 DM
Hepatic impairment
1
Yes
Limited
No
Yes
23
Metformin + Linagliptin
Trajenta Duo
Combo (Biguanide+DPP4)
—
Oral
2.5/500 – 2.5/1000 mg BID
CKD
—
1
Minimal
Limited
No
Yes
24
Metformin + Dapagliflozin
Xigduo XR
Combo (Biguanide+SGLT2)
XR
Oral
5/1000 mg once/twice daily
T2DM + CVD/CKD
eGFR < 30
1
Yes
Limited
No
Yes
25
Metformin + Empagliflozin
Synjardy
Combo (Biguanide+SGLT2)
—
Oral
5/1000 or 12.5/1000 mg BID
Type 2 DM + CV benefit
eGFR < 30
1
Yes
Limited
No
Yes
26
Metformin + Canagliflozin
Vokanamet
Combo (Biguanide+SGLT2)
—
Oral
50/500 – 150/1000 mg BID
Type 2 DM obese
eGFR < 30
2
Yes
Limited
No
Yes
27
Insulin Degludec + Liraglutide
Xultophy
Combo (Insulin+GLP1)
Injectable
SC
Titrated 10–50 units/day
T2DM uncontrolled on OAD
Pregnancy, Type 1 DM
1
Yes
No
Yes
No
28
Insulin Glargine + Lixisenatide
Suliqua
Combo (Insulin+GLP1)
Injectable
SC
10–60 units/day
Type 2 DM uncontrolled
Type 1 DM
2
Yes
No
Yes
No
29
Glimepiride + Metformin
Amaryl M; Glimepil M; Diamicron M
Combo (Sulfonylurea+Biguanide)
—
Oral
1/500 – 2/500 mg BID
Type 2 DM
Elderly, Hypoglycemia
2
Yes
Limited
No
Yes
30
Pioglitazone + Metformin
Competact
Combo (TZD+Biguanide)
—
Oral
15/500 mg daily
Insulin resistance + NAFLD
Heart failure, Edema
2
Yes
Limited
No
Yes
2️⃣ Clinical Scenarios (1–15)
Scenario_ID
Diabetes_Type
Age_Group
CKD_Stage
Pregnancy
Complications
Goal
Preferred_Categories
Avoid_Categories
Suggested_Labs
Follow_Up_Interval
Notes
1
Type 2
Adult
Normal
No
Obesity
Weight loss + HbA1c
Biguanide, GLP1, SGLT2
Sulfonylurea, TZD
Fasting glucose, HbA1c, Lipid profile, Liver function
3 months
Focus on weight management + lifestyle
2
Type 2
Adult
CKD 3
No
CV Disease
CV protection
SGLT2 (if eGFR ok), DPP4, GLP1
Metformin (if eGFR < 30), TZD
Fasting glucose, HbA1c, Lipid profile, Kidney function, ECG
3 months
Cardiovascular protection priority
3
Type 2
Elderly
CKD 4
No
Hypoglycemia risk
Safe glycemic control
DPP4, GLP1
Sulfonylurea, Insulin
Fasting glucose, HbA1c, Kidney function
3 months
Avoid hypoglycemia; monitor renal function
4
Type 1
Any
Any
No
—
Glycemic control
Insulin only
Oral hypoglycemics
Fasting glucose, HbA1c, Ketones if needed
3 months
Insulin adjustment essential
5
Type 2
Adult
Normal
Yes
—
Safe pregnancy
Insulin
Metformin, Sulfonylurea, SGLT2, GLP1
Fasting glucose, HbA1c, Liver & Kidney function
Monthly
Frequent monitoring required
6
Type 2
Adult
Normal
No
NAFLD
Insulin sensitivity
TZD, Metformin
Sulfonylurea, SGLT2
Fasting glucose, HbA1c, Liver function
3 months
Focus on insulin sensitivity, avoid weight gain
7
Type 2
Adult
Normal
No
Heart failure
Reduce fluid retention + glycemic control
SGLT2, DPP4
TZD
Fasting glucose, HbA1c, Kidney function, BNP/NT-proBNP
3 months
Monitor heart failure status
8
Type 2
Elderly
CKD 2–3
No
Frailty
Minimize hypoglycemia
DPP4, GLP1
Sulfonylurea, Insulin
Fasting glucose, HbA1c, Kidney function
3 months
Elderly care, hypoglycemia prevention
9
Type 2
Adult
CKD 5 / Dialysis
No
—
Glycemic control
Insulin (adjust dose)
Metformin, SGLT2, TZD
Fasting glucose, HbA1c, Kidney function
Monthly or per dialysis schedule
Dose adjustments essential
10
Type 2
Adult
Normal
No
Obesity + CVD
Weight loss + CV protection
GLP1, SGLT2
Sulfonylurea, TZD
Fasting glucose, HbA1c, Lipid profile
3 months
Weight loss + cardiovascular protection
11
Type 2
Adult
Normal
No
Postprandial hyperglycemia
Control PP glucose
Meglitinide, Alpha-glucosidase
Sulfonylurea, TZD
Postprandial glucose, HbA1c
3 months
Focus on postprandial control
12
Type 2
Adult
CKD 3
No
Hypoglycemia risk
Safe glycemic control
DPP4, GLP1
Sulfonylurea, Insulin
Fasting glucose, HbA1c, Kidney function
3 months
Hypoglycemia prevention
13
Type 2
Adult
Normal
No
Non-obese
HbA1c reduction
Sulfonylurea, Metformin
TZD
Fasting glucose, HbA1c
3 months
Non-obese T2DM; standard monitoring
14
Type 2
Adult
Normal
No
Obese
Weight loss + HbA1c
Metformin, GLP1
Sulfonylurea
Fasting glucose, HbA1c, Lipid profile
3 months
Weight management focus
15
Type 2
Adult
Normal
No
Insulin resistance
Improve insulin sensitivity
Metformin, TZD
Sulfonylurea
Fasting glucose, HbA1c, Liver function
3 months
Improve insulin sensitivity; monitor TZD effects
3️⃣ Patient Input (Sheet1)
Field
Value
Name
Age
Diabetes_Type
Type 1 / Type 2
CKD_Stage
Normal / CKD 1–5
Pregnancy
Yes / No
Complications
Obesity / CVD / NAFLD / Heart failure / Hypoglycemia risk / …
Goal
HbA1c control / Weight loss / CV protection / Insulin sensitivity
4️⃣ Output Table (Sheet4)
Generic
Brand
Standard_Dose
Suggested_Labs
Follow_Up_Interval
Notes
[دواء 1]
[اسم تجاري]
[جرعة]
[Labs من Scenario]
[Interval]
[Notes]
[دواء 2]
[اسم تجاري]
[جرعة]
[Labs من Scenario]
[Interval]
[Notes]
…
ساحة النقاش